Please login to the form below

Not currently logged in
Email:
Password:

ISIS-APOCIII Rx

This page shows the latest ISIS-APOCIII Rx news and features for those working in and with pharma, biotech and healthcare.

Biogen Idec gets exclusive access to Isis' neurology R&D

Biogen Idec gets exclusive access to Isis' neurology R&D

In early 2012, Biogen Idec tapped into Isis' antisense technology to try to develop a new drug called ISIS-SMN Rx to treat spinal muscular atrophy. ... Meanwhile, Isis has also just reported encouraging data from a phase II trial ISIS-APOCIII Rx for

Latest news

  • Isis rises on positive triglyceride drug data Isis rises on positive triglyceride drug data

    ISIS-APOCIII Rx can cause triglycerides to drop 75 per cent. Antisense specialist Isis Pharmaceuticals shares leapt this week after the company reported positive data with its triglyceride-lowering drug candidate. ... ISIS-APOCIII Rx achieved a

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics